Q1 EPS Estimates for Globus Medical Cut by Zacks Research

Globus Medical, Inc. (NYSE:GMED) – Stock analysts at Zacks Research decreased their Q1 2025 earnings per share (EPS) estimates for shares of Globus Medical in a note issued to investors on Thursday, March 13th. Zacks Research analyst R. Department now anticipates that the medical device company will post earnings per share of $0.73 for the quarter, down from their prior estimate of $0.79. The consensus estimate for Globus Medical’s current full-year earnings is $3.44 per share. Zacks Research also issued estimates for Globus Medical’s Q3 2025 earnings at $0.87 EPS, Q4 2025 earnings at $0.97 EPS, Q1 2026 earnings at $0.87 EPS, Q2 2026 earnings at $0.92 EPS, Q3 2026 earnings at $0.99 EPS, Q4 2026 earnings at $1.14 EPS and FY2027 earnings at $4.49 EPS.

Several other brokerages also recently commented on GMED. StockNews.com upgraded Globus Medical from a “hold” rating to a “buy” rating in a research note on Thursday, March 13th. Needham & Company LLC restated a “hold” rating on shares of Globus Medical in a research note on Friday, February 21st. Wells Fargo & Company reduced their target price on Globus Medical from $95.00 to $93.00 and set an “overweight” rating for the company in a research note on Friday, February 21st. Stifel Nicolaus raised their target price on Globus Medical from $92.00 to $94.00 and gave the company a “buy” rating in a research note on Friday, February 21st. Finally, Roth Mkm lifted their price target on Globus Medical from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Tuesday, December 17th. Three research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. According to MarketBeat.com, Globus Medical presently has an average rating of “Moderate Buy” and a consensus price target of $97.82.

Globus Medical Price Performance

Shares of GMED opened at $72.16 on Monday. The stock has a 50-day moving average of $84.63 and a 200-day moving average of $79.80. The company has a market cap of $9.93 billion, a PE ratio of 96.22, a P/E/G ratio of 1.61 and a beta of 1.19. Globus Medical has a one year low of $49.33 and a one year high of $94.93.

Globus Medical (NYSE:GMED) last issued its quarterly earnings results on Thursday, February 20th. The medical device company reported $0.84 earnings per share for the quarter, topping analysts’ consensus estimates of $0.74 by $0.10. The firm had revenue of $657.29 million during the quarter, compared to the consensus estimate of $646.19 million. Globus Medical had a return on equity of 10.83% and a net margin of 4.09%.

Insiders Place Their Bets

In other Globus Medical news, CFO Keith W. Pfeil sold 14,167 shares of Globus Medical stock in a transaction that occurred on Friday, January 10th. The shares were sold at an average price of $88.29, for a total transaction of $1,250,804.43. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Insiders own 18.54% of the company’s stock.

Hedge Funds Weigh In On Globus Medical

Hedge funds have recently modified their holdings of the company. Crossmark Global Holdings Inc. raised its holdings in shares of Globus Medical by 6.0% in the 3rd quarter. Crossmark Global Holdings Inc. now owns 7,750 shares of the medical device company’s stock worth $554,000 after purchasing an additional 436 shares during the period. KBC Group NV raised its holdings in shares of Globus Medical by 0.5% in the 3rd quarter. KBC Group NV now owns 45,505 shares of the medical device company’s stock worth $3,255,000 after purchasing an additional 237 shares during the period. Quest Partners LLC bought a new stake in shares of Globus Medical in the 3rd quarter worth approximately $523,000. Pathstone Holdings LLC raised its holdings in shares of Globus Medical by 2.6% in the 3rd quarter. Pathstone Holdings LLC now owns 41,007 shares of the medical device company’s stock worth $2,934,000 after purchasing an additional 1,055 shares during the period. Finally, Segall Bryant & Hamill LLC raised its holdings in shares of Globus Medical by 7.2% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 387,737 shares of the medical device company’s stock worth $27,739,000 after purchasing an additional 26,047 shares during the period. Institutional investors own 95.16% of the company’s stock.

Globus Medical Company Profile

Globus Medical, Inc, a medical device company, develops and commercializes healthcare solutions for patients with musculoskeletal disorders in the United States and internationally. The company offers spine products, such as traditional fusion implants comprising pedicle screw and rod systems, plating systems, intervertebral spacers, and corpectomy devices for treating degenerative and congenital conditions, deformity, tumors, and trauma injuries; treatment options for motion preservation technologies that consist of dynamic stabilization, total disc replacement, and interspinous distraction devices; interventional solutions to treat vertebral compression fractures; and regenerative biologic products comprising of allografts and synthetic alternatives.